Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience to Showcase Progression in Human Surrogate Trials

Published: Wednesday, May 21, 2014
Last Updated: Wednesday, May 21, 2014
Bookmark and Share
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.

Crown Bioscience, Inc. will showcase their human surrogate trial platform at the 50th Annual ASCO Conference, taking place in Chicago, US, between 30th May and 3rd June. The HuTrialTM platform enables drug discovery and development companies to optimize their screening processes to ensure that only the most effective candidates are accelerated through to the clinic and onto improving patient care.

The most significant limitation to the development of new treatments in oncology is undoubtedly cost prohibition, as the attrition of a drug in the final stages of clinical trials carries significant financial implications for drug development. The HuTrial substitutes Phase-II trials at reduced cost, providing the opportunity for early decision making regarding drug candidate progression and significantly decreasing the risk of promoting ineffective therapeutics through the later stages of clinical testing.

The HuTrialTM platform substantially reduces the time and cost of phase-II trials and when used to identify patient biomarkers, it can effectively predict the clinical response of a prospective candidate before undergoing rigorous clinical testing. By evaluating all prospective treatments, surrogate trials can improve the success rate with which effective therapeutics reach the clinic and help reduce the chances of patients experiencing harmful or unpleasant side effects. HuTrials are conducted using Crown’s HuPrime® patient derived xenografts (PDX), where primary tumor cells are extracted directly from a patient and transplanted into surrogate, in most cases immunodeficient mice. As the cancer develops, prospective treatments can be administered to the surrogate host and the efficacy of prospective drug candidates can be observed and evaluated.

Jean-Pierre Wery, the President of Crown Bioscience comments; “At Crown Bioscience we are committed to improving the decision making process involved in submitting drug candidates for phase II and III clinical trials. As the most significant factor affecting the advancement of drug development is the cost of drug attrition in the later stages of clinical trials, it is important that we ensure that our clients do not waste resources on ineffective treatments. If we can assist them in identifying promising candidates early on, we can improve the rate at which effective new treatments are delivered into the clinic to improve patient outcomes. The HuTrialTM platform has the potential to help alleviate the socio-economic burden cancer has on the healthcare industry and assist in the global effort to convert cancer from a terminal condition to a chronic disease.”

The acclaimed ASCO Annual Meeting is attended by more than 25,000 oncology professionals, across a broad range of specialties. The itinerary includes workshops, education sessions, discussions, symposia and poster presentations to highlight clinical issues and frontline research and discovery. By bringing together individuals at the forefront of their respective fields, ASCO endeavors to unite the international oncological community with a view to sharing expertise, exploring new ideas, and further developing clinical and research techniques.




Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!